Malaria Vaccines Market Analysis & Forecast: 2024-2031

Malaria Vaccines Market Size and Forecast – 2024 to 2031

The Global Malaria Vaccines Market is estimated to be valued at USD 550.1 Mn in 2024 and is expected to reach USD 1,252.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2031.

Key Takeaways of the Malaria Vaccines Market:

• Based on vaccine type, the pre-erythrocytic vaccines segment is expected to contribute the highest share of the market with 42.1% in 2024
• Based on agent, the Plasmodium Falciparum segment is expected to contribute the highest share of the market with 45.6% in 2024
• Based on age, the pediatric segment is expected to contribute the highest share of the market with 52.3% in 2024
• North America is expected to top the global market with 38.4% share, followed by Asia Pacific with 27.7% share in 2024

Market Overview:

Factors, such as rising global incidences of malaria, growing government support, and increasing R&D funding by private and public organizations, are expected to drive the demand for novel and effective malaria vaccines. Currently, there is no highly effective vaccine for malaria however few vaccines are under development which shows promise. If approved, these vaccines could help reduce malaria burden globally and complement other preventive and therapeutic measures. Furthermore, initiatives by WHO to eradicate malaria by 2030 will further contribute towards the growth of this market. Developme

Segmental Insights

To learn more about this report, Request sample copy

Vaccine Type Insights - Developments in Antigen Identification and Cultivation Drive Pre-Erythrocytic Vaccine Dominance

In terms of vaccine type, the pre-erythrocytic vaccines segment is expected to contribute the highest share of the market with 42.1% in 2024 owing to advancements in identifying and cultivating antigens unique to the liver stage of malaria infection. Extensive research efforts over the past decades have enabled scientists to pinpoint proteins and cellular structures expressed primarily during invasion and early liver stage development of the Plasmodium parasite. Technologies like antigen banks, -omics analyses, and high-throughput screening enable the rapid evaluation of thousands of potential targets. Additionally, advancements in culture methods have improved access to pre-erythrocytic stage Plasmodium, supporting experimental vaccine design and testing efforts. These scientific capabilities have translated into a rich portfolio of pre-clinical and clinical-stage pre-erythrocytic vaccine candidates with novel mechanisms of action. The promising efficacy and safety shown by leading products, if successfully translated to widespread use, could help eliminate malaria transmission in endemic regions.

Agent Insights - Plasmodium Falciparum Prevalence Drives Agent-specific Vaccine Development

In terms of agent, the Plasmodium Falciparum segment is expected to contribute the highest share of the market with 45.6% in 2024 due to its high disease burden globally. P. falciparum is the most prevalent malaria parasite in vast regions of sub-Saharan Africa and is responsible for the vast majority of severe illness and death from the disease. Given the heavy toll P. falciparum extracts, researchers have prioritized the development of agent-specific vaccines targeting this parasite. Key antigens are believed to play an important role during invasion and replication are actively under investigation. Clinical trials have evaluated candidates designed to induce protective immunological memory against P. falciparum.

Age Insights - Emphasis on Early Childhood Immunization Fuels Pediatric Vaccine Dominance

In terms of age, the pediatric segment is expected to contribute the highest share of the market with 52.3% in 2024 due to an emphasis on early childhood immunization in malaria-endemic regions. Young children bear the heaviest malaria disease burden yet are often ineligible for established prevention methods such as antimalarial drugs or insecticide-treated bed nets. Vaccines could play a particularly impactful role by boosting an infant's innate immune defenses before first exposure to the malaria parasite. Regulatory guidelines support accelerated development pathways for pediatric vaccines filling critical public health needs. Clinical trials commonly enroll infants and small children to evaluate vaccine safety and efficacy in the highest risk population.

Regional Insights

To learn more about this report, Request sample copy

North America Malaria Vaccines Market Trends

North America’s dominance in the malaria vaccines market with a share of 38.4% in 2024 can be attributed to a strong presence of major pharmaceutical companies and favorable government policies supporting research and development activities in the region. The U.S. is home to most leading vaccine manufacturers like Novavax Inc. with extensive investments in malaria vaccine development programs.

Asia Pacific Malaria Vaccines Market Trends

The Asia Pacific region exhibits the fastest growth with an estimated 27.7% share in 2024 due to rising disease burden and increasing demand for novel vaccines in highly populated countries like India and China. Substantial funding from public-private partnerships is accelerating clinical trials and vaccine access in these developing markets.

Malaria Vaccines Market Outlook for Key Countries

Central African Republic Malaria Vaccines Market Trends

The Central African Republic (CAR) plays a significant role in driving the global malaria vaccines market growth due to its high malaria incidence & R&D activities. For instance, in May 2024, the Central African Republic (CAR) introduced the R21/Matrix-M malaria vaccine into its routine Expanded Programme on Immunization (EPI), becoming the fourth country to do so after Côte d'Ivoire. The R21 vaccine, recommended by the World Health Organization, aims to reduce malaria-related deaths in endemic areas.

Brazil Malaria Vaccines Market Trends

Brazil plays a crucial role in driving the growth of the global malaria vaccines market due to its proactive approach in tackling malaria. For instance, in June 2023, Medicines for Malaria Venture (MMV) and PATH announced that Brazil has become the first malaria-endemic country to incorporate the STANDARD G6PD Test and single dose tafenoquine into its public health system for treating Plasmodium vivax (P. vivax) malaria. The Brazilian National Malaria Program, focused on malaria elimination, aims to reduce relapses and improve access to effective treatments for those affected by P. vivax malaria.

Ghana Malaria Vaccines Market Trends

Ghana has been a pioneer in malaria vaccine implementation. In April 2021, the country launched the Malaria Vaccine Implementation Programme (MVIP) in collaboration with WHO, GSK plc., a pharmaceutical company, and other partners, aiming to assess the feasibility of large-scale malaria vaccination.

Market Players, Key Devlopment, and Competitive Intelligence

Get actionable strategies to beat competition: Request sample copy

Key Developments:

• In May 2024, United Nations International Children's Emergency FundUNICEF, delivered over 43,000 doses of the R21/Matrix-M Malaria Vaccine to Bangui, Central African Republic, with 120,000 additional doses arriving soon. This marks the first use of the R21 vaccine in routine childhood immunization. R21, the second malaria vaccine recommended by the World Health Organization (WHO), joins the RTS, S vaccine in scaling up malaria vaccination across Africa. Funded by Gavi, the Vaccine Alliance, this expanded supply is set to transform child health and survival in endemic areas.
• In October 2023, UNICEF, the United Nations agency for children, announced a long-term agreement with Serum Life Sciences to secure the supply of the R21/Matrix-M Malaria Vaccine, conditional on World Health Organization (WHO) pre-qualification. Deliveries are expected to begin mid-2024, complementing the rollout of the first malaria vaccine, RTS, S, starting late 2023.
• In September 2022, GSK plc, a biopharma company, announced that Mosquirix (RTS, S/AS01), its groundbreaking malaria vaccine, has received World Health Organization (WHO) prequalification, the first for a malaria vaccine. This milestone enables procurement by UN agencies like UNICEF in collaboration with Gavi, the Vaccine Alliance, for rollout in countries with moderate to high Plasmodium falciparum malaria transmission.

Top Strategies Followed by Global Malaria Vaccines Market Players

• Leading companies prioritize substantial research and development to innovate high-performance malaria vaccines
  • For instance, the Serum Institute of India, in collaboration with the University of Oxford, developed the R21/Matrix-M malaria vaccine, which received prequalification status from the World Health Organization (WHO) in 2024, enabling mass distribution
• Mid-level companies are focusing on delivering budget-friendly products
  • For example, Hilleman Laboratories, a joint venture between Merck & Co., Inc. and the Wellcome Trust, is dedicated to developing affordable vaccines for developing nations. They have undertaken projects such as creating a heat-stable rotavirus vaccine and an optimized cholera vaccine, aiming to reduce production costs and improve accessibility in low-resource settings.
• Small players often target niche markets. For instance, in 2024, Ocean Biomedical, a biopharmaceutical company based in Providence, Rhode Island, U.S., announced the discovery of a malaria vaccine. This development underscores the company's commitment to addressing malaria through innovative solutions.

Emerging Startups - Malaria Vaccines Industry Ecosystem

• Startups like BioNTech are developing advanced technologies, including mRNA-based vaccines for malaria. Their innovative approach could significantly impact market dynamics by providing faster and more effective vaccine solutions.
• Startups are increasingly focusing on sustainability. For example, a startup named EcoVax is working on eco-friendly vaccine production methods, utilizing recycled materials to reduce environmental impact.
• Emerging startups are addressing unique market needs. For instance, a startup called MalariaTech is developing a vaccine specifically for Plasmodium vivax, filling a critical gap in the market. MalariaTech is concentrating on a vaccine specifically for Plasmodium vivax, the most widespread form of malaria. This vaccine aims to fill a significant gap in the market, as current vaccines and treatments are primarily effective against falciparum. P. vivax presents unique challenges in terms of its ability to relapse and its complex life cycle, making the development of a targeted vaccine crucial.

Market Report Scope

Market Dynamics

Discover market dynamics shaping the industry: Request sample copy

Malaria Vaccines Market Growth Factors - Increasing prevalence of malaria in endemic regions

Malaria continues to be a major challenge for many developing nations, particularly in sub-Saharan Africa. For decades, the disease has burdened these resource-limited regions, hindered economic growth and caused preventable deaths year after year. While efforts have been made to curb the spread through vector control measures and anti-malarial drugs, the complex transmission dynamics and ever-evolving parasite resistance poses a constant challenge. In December 2021, according to data from WHO, there were an estimated 241 million cases of malaria in 2020 compared to 227 million cases in 2019, maintaining an unacceptable status-quo. Most casualties occurred among children in Africa, the group most vulnerable to its severe complications. Prospering nations have long gained control through sustained strategies but for many tropical and subtropical developing countries, malaria remains entrenched in their healthcare systems, social fabric, and national economy.

Malaria Vaccines Market Challenge - High costs associated with vaccine development and distribution

One of the major challenges faced by the global malaria vaccines market is the high costs associated with vaccine development and distribution. Developing an effective vaccine for malaria is an immense challenge given the complexity of the parasite's life cycle. Extensive research and clinical trials are required to establish a vaccine's safety and efficacy. This lengthy and expensive research and development process significantly increases the costs for manufacturers. Additionally, efficient supply chain and effective distribution networks are required to deliver the vaccines to populations in endemic regions. This involves establishing infrastructure for cold chain storage and transportation in remote areas with inadequate medical facilities and limited transport connectivity. The costs of setting up such infrastructure and operations further adds to the financial burden. Resource-constrained government health budgets and lack of commercial incentives also make private investments difficult.

Malaria Vaccines Market Opportunity - Rising focus on public health initiatives and malaria elimination programs

One of the major opportunities for the global malaria vaccines market is the rising focus on public health initiatives and malaria elimination programs around the world. Governments and international organizations have intensified efforts towards eradicating malaria through a combination of preventive, diagnostic, and treatment measures. Mass drug administration campaigns, insecticide treated bed nets, and rapid diagnostic tests are being scaled up through sustained funding. Global initiatives like the WHO's Global Technical Strategy have provided an impetus towards introducing malaria vaccines as an additional control tool. Increased advocacy and large donation-funded pilot programs also aim to develop sustainable commercial models. Successful development of even a partially effective vaccine against the deadliest Plasmodium Falciparum parasite could significantly boost such public health efforts. This presents considerable commercial opportunities for malaria vaccine manufacturers in partnering with governments and global health agencies.

Analyst Opinion (Expert Opinion)

• The global malaria vaccines market holds promise driven by increasing government focus on malaria eradication and rising funding for malaria vaccination programs. Regulatory approvals for RTS, S, a malaria vaccine and rising malaria cases in Africa and Asia Pacific regions have boosted market opportunities. Lack of durable immunity and efficacy concerns surrounding RTS, S vaccine pose challenges to market growth. Additionally, the tropical geographical coverage of malaria affects vaccine accessibility and distribution challenges in remote areas.
• North America and Europe are expected to see steady demand for malaria vaccines from travelers and expatriates to endemic regions. However, Africa and Asia Pacific regions with heavy disease burden will dominate the market owing to massive vaccination campaigns proposed by WHO. Countries like India, Nigeria, and the Democratic Republic of the Congo with over 35 million annual malaria cases each, present significant market potential.
• Continued R&D efforts to develop highly effective and long-lasting vaccine candidates beyond RTS, S could unlock greater opportunities. Successful partnerships between drug makers, global health organizations, and funding agencies will be critical to accelerate vaccine accessibility. Furthermore, the integration of vaccines into broader malaria control programs could facilitate large scale adoption.

Market Segmentation

•  Vaccine Type Insights (Revenue, USD Mn, 2019 - 2031)
• • Pre-Erythrocytic Vaccines
  • Erythrocytic Vaccines
  • Multi-Antigen Vaccines
•  Agent Insights (Revenue, USD Mn, 2019 - 2031)
• • Plasmodium Falciparum
  • Plasmodium Vivax
  • Anopheles Species
•  Age Insights (Revenue, USD Mn, 2019 - 2031)
• • Pediatric
  • Adult
•  Distribution Channel Insights (Revenue, USD Mn, 2019 - 2031)
• • Public
  • Private
•  End Users Insights (Revenue, USD Mn, 2019 - 2031)
• • Hospitals
  • Specialty Clinics
  • Community Health Centers
  • Homecare
• Regional Insights (Revenue, USD Mn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • GlaxoSmithKline plc
  • Sanaria Inc.
  • Nobelpharma Co.
  • Sumaya Biotech
  • GenVec
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Johnson & Johnson
  • Bharat Biotech
  • Serum Institute of India
  • Takeda Pharmaceutical Company
  • Novavax, Inc.
  • Inovio Pharmaceuticals
  • Vaxart, Inc.
  • BioNTech SE